ArticleScientific reports2025
Staphyloxanthin loaded niosomal nanocarrier augments its anthelmintic activity against Trichinella spiralis infection in mice.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Staphylococcus aureus's golden-yellow pigment staphyloxanthin: production enhancement, analytical characterization, and biological attributes.Microbial cell factories · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trichinellosis, a resurgent zoonotic infestation, threatens public health due to recorded human outbreaks in various nations. The emergence of treatment resistance necessitates the exploration of efficient natural alternatives. Staphyloxanthin (STX), a membrane-associated secondary metabolite carotenoid pigment, underscores pro-oxidative traits, positioning it as a novel therapeutic candidate. Nanostructures demonstrated encouraging promise in overcoming low oral bioavailability, which could undermine the efficacy. Hence, the therapeutic outcome of STX-loaded niosomes was scrutinized both in vitro and in vivo. In this study, the prepared niosomal nanovesicles exhibited a spherical form in the nanoscale spectrum. Our in vitro findings demonstrated that STX markedly diminished larval viability, associated with excessive cuticular deformities, numerous notches, and membrane blebbing. The preclinical evaluation revealed that the oral delivery of STX-niosomes showed a superiority of therapeutic efficacy in mice compared to the reference drug. This was reflected by the eradicated adult worms, enhanced histopathological attributes, and reduced larval count. It is noteworthy that the biological findings revealed a significant reduction in the inflammatory expression of TNF-α surrounding trichina capsules. The relationship between STX and the parasite was elucidated, with the promising antiparasitic efficacy being further corroborated through in silico homology modelling and molecular docking approaches. The 3D-modelled target protein structures exhibited excellent quality factors and favourable Ramachandran plot statistics. Intriguingly, in silico docking results obviously revealed the potential affinity of STX to bind and block target protein receptors. In conclusion, our results suggested that STX pigment may serve as a promising pioneering alternative in the anthelmintic fight against trichinellosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.